ReviewResearch (Washington, D.C.)2024
Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy.
Review in Research (Washington, D.C.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Carrier-Free Nanoassembly Suppresses Phase Separation via Ribosome-Inspired Crowding Control for Enhanced Chemo-Immunotherapy.ACS nano · 2026Article
- Frozen melanoma tissues yield extracellular vesicles with preserved diagnostic and immunogenic properties.BMC medicine · 2026Article
- Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy.Journal of extracellular vesicles · 2026Article
- Regulation of Pore Evolution via Progressive Electroporation Enhanced Intracellular Molecule Transport.Research (Washington, D.C.) · 2026Article
- A Bioinspired Approach to Next-Generation Vaccines in Solid Tumors with Engineered Cell Membranes.Research (Washington, D.C.) · 2026Review
- Co-Extracellular Vesicles Delivery System Enhances Immunochemotherapy for Glioblastoma.Research (Washington, D.C.) · 2026Article
- Plant-Derived Extracellular-Vesicle-Like Particles: Immune Regulation and Disease Therapy.Research (Washington, D.C.) · 2026Review
- The potential of extracellular vesicle-derived nanosystems in precision oncology.Nanomedicine (London, England) · 2025Article
- Engineering CRISPR System-Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Extracellular Vesicles in cancer: from isolation and characterization to metastasis, drug resistance, and clinical applications.BMC cancer · 2025Review
- Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management.The EPMA journal · 2025Review
- Emerging role of exosomes in cancer therapy: progress and challenges.Molecular cancer · 2025Review
- Advanced Nanoprobe Strategies for Imaging Macrophage Polarization in Cancer Immunology.Research (Washington, D.C.) · 2025Review
- The Role of UFMylation in the Development and Progression of Gastric Cancer.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Extracellular vesicles (EVs) are lipid bilayer-enclosed vesicles released by cells. EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells. These vesicles act as mediators of intercellular communication and thus play a crucial role in various physiological and pathological processes. Moreover, EVs hold promise for clinical use. They have been explored as drug delivery vehicles, therapeutic agents, and targets for disease diagnosis. In the landscape of cancer research, while strides have been made in EV-focused cancer physiopathology, liquid biopsy, and drug delivery, the exploration of EVs as immunotherapeutic agents may not have seen substantial progress to date. Despite promising findings reported in cell and animal studies, the clinical translation of EV-based cancer immunotherapeutics encounters challenges. Here, we review the existing strategies used in EV-based cancer immunotherapy, aiming to propel the development of this emerging yet crucial field.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.